According to a report published by Fact.MR, the global peptide based cancer therapeutics market is poised to surpass the market valuation of US$ 11,000 Mn by the end of 2022, owing to multiple factors contributing to this boom.
Medical institutions across the world are ramping up their efforts towards the development of effective therapeutic drugs for cancer treatment. In addition to this, investors are underpinning the initiatives of healthcare organizations by funding their researches. With the report produced by the World Health Organization (WHO) stating the occurrence of over 8 Mn deaths in 2015 backed by the pervasiveness of cancer, proliferating adoption of advanced peptide based cancer therapeutic is witnessed. A host of these factors have contributed to the growing size of the peptide-based cancer therapeutics market at the global level with an estimated CAGR of over 9% through 2022.\
North America enjoys a large concentration of peptide based cancer therapeutic drug manufacturers, which has reflected positively on the growth of this market. Additionally, the advanced healthcare infrastructures have also been a driving factor fostering the growth of this market.
On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.
Peptide Based Cancer Therapeutics Market: Synopsis of the Report
The primary aim of this market study on peptide-based cancer therapeutics is to lend a holistic view of the market to the stakeholders. The forecast has been done for the period from 2017 to 2022. Here, 2017 is considered as the base year and prediction has been provided for the duration 2018 to 2022. The market evaluation has been done in revenue (US$ Mn).
The report commences with a detailed executive summary, which further provides the scope of the study. An analysis of the year-over-year growth is incorporated in the study, with a view to providing information on the growth patterns of the market. In the succeeding section of the report, macroeconomic and microeconomic factors influencing the market growth has been discussed and included. The report delineates demand drivers, opportunities, threats, restraints and challenging, impacting the market at the global level. A segment-wise analysis is also included in the report, in order to lend a decisive view of the market to the stakeholders.
Browse Full Report with ToC Here:
https://www.factmr.com/report/179/peptide-based-cancer-therapeutics-market
An analysis of the supply chain and average pricing is discussed in the report to understand the dynamics of the peptide-based cancer therapeutics market. Evaluation of the attractiveness of the market has been carried out on the basis of region, drug, and distribution channel.
Outline of Dominant Competitors and Geographies Influencing the Growth of the Peptide-based Cancer Therapeutics Market
The regions analyzed in the report consist of Latin America, North America, Europe, Japan, Asia Pacific except Japan (APEJ), and the Middle East and Africa (MEA). The regions have been analyzed keeping the segments – drug and distribution channel and their revenue share to the global market in mind.
The leading companies profiled in this market study includes Allergan plc, Valeant Pharmaceuticals International, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Johnson & Johnson, and Abbott, Pfizer Inc. An in-depth company overview, business strategies, market size, and recent developments are discussed in this report. These insights incorporated in the report will aid the drug manufacturers, raw material distributors, and research institutes in devising informed strategies to capture a large market share.
Medical institutions across the world are ramping up their efforts towards the development of effective therapeutic drugs for cancer treatment. In addition to this, investors are underpinning the initiatives of healthcare organizations by funding their researches. With the report produced by the World Health Organization (WHO) stating the occurrence of over 8 Mn deaths in 2015 backed by the pervasiveness of cancer, proliferating adoption of advanced peptide based cancer therapeutic is witnessed. A host of these factors have contributed to the growing size of the peptide-based cancer therapeutics market at the global level with an estimated CAGR of over 9% through 2022.\
North America enjoys a large concentration of peptide based cancer therapeutic drug manufacturers, which has reflected positively on the growth of this market. Additionally, the advanced healthcare infrastructures have also been a driving factor fostering the growth of this market.
On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.
Peptide Based Cancer Therapeutics Market: Synopsis of the Report
The primary aim of this market study on peptide-based cancer therapeutics is to lend a holistic view of the market to the stakeholders. The forecast has been done for the period from 2017 to 2022. Here, 2017 is considered as the base year and prediction has been provided for the duration 2018 to 2022. The market evaluation has been done in revenue (US$ Mn).
The report commences with a detailed executive summary, which further provides the scope of the study. An analysis of the year-over-year growth is incorporated in the study, with a view to providing information on the growth patterns of the market. In the succeeding section of the report, macroeconomic and microeconomic factors influencing the market growth has been discussed and included. The report delineates demand drivers, opportunities, threats, restraints and challenging, impacting the market at the global level. A segment-wise analysis is also included in the report, in order to lend a decisive view of the market to the stakeholders.
Browse Full Report with ToC Here:
https://www.factmr.com/report/179/peptide-based-cancer-therapeutics-market
An analysis of the supply chain and average pricing is discussed in the report to understand the dynamics of the peptide-based cancer therapeutics market. Evaluation of the attractiveness of the market has been carried out on the basis of region, drug, and distribution channel.
Outline of Dominant Competitors and Geographies Influencing the Growth of the Peptide-based Cancer Therapeutics Market
The regions analyzed in the report consist of Latin America, North America, Europe, Japan, Asia Pacific except Japan (APEJ), and the Middle East and Africa (MEA). The regions have been analyzed keeping the segments – drug and distribution channel and their revenue share to the global market in mind.
The leading companies profiled in this market study includes Allergan plc, Valeant Pharmaceuticals International, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Johnson & Johnson, and Abbott, Pfizer Inc. An in-depth company overview, business strategies, market size, and recent developments are discussed in this report. These insights incorporated in the report will aid the drug manufacturers, raw material distributors, and research institutes in devising informed strategies to capture a large market share.
Comments
Post a Comment